← United States · Coverage record
US · SEC FORM 4
Xilio Therapeutics, Inc.
XLO · Nasdaq · CIK 0001840233 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-03-26 · Shannon James Samuel.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 410,050
- Previous report
- 412,963
- Avg daily volume
- 9,210
- Days to cover
- 44.5
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | Purchase (P) | Common Stock | 5,000 | USD 8.79 | USD 43,950 | SEC filing ↗ |
| 2025-06-17 | Shannon James Samuel | Purchase (P) | Common Stock | 25,000 | USD 0.69 | USD 17,250 | SEC filing ↗ |
| 2025-06-16 | Shannon James Samuel | Purchase (P) | Common Stock | 45,000 | USD 0.69 | USD 31,050 | SEC filing ↗ |
| 2025-06-16 | Russo Rene | Purchase (P) | Common Stock | 36,289 | USD 0.68 | USD 24,677 | SEC filing ↗ |
| 2024-12-18 | GILEAD SCIENCES, INC. | Purchase (P) | Common Stock | 1,759,978 | USD 1.04 | USD 1,830,377 | SEC filing ↗ |
| 2024-04-02 | GILEAD SCIENCES, INC. | Purchase (P) | Common Stock | 485,250 | USD 0.76 | USD 368,790 | SEC filing ↗ |
| 2021-12-10 | BCIP Life Sciences Associates, LP; BCLS II Investco, LP; BCLS II Investo (GP), LLC; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors II, LLC; Bain Capital Life Sciences Investors, LLC | Purchase (P) | Common Stock | 25,000 | USD 9.65 | USD 241,168 | SEC filing ↗ |
| 2021-12-09 | BCIP Life Sciences Associates, LP; BCLS II Investco, LP; BCLS II Investo (GP), LLC; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors II, LLC; Bain Capital Life Sciences Investors, LLC | Purchase (P) | Common Stock | 4,011 | USD 9.84 | USD 39,468 | SEC filing ↗ |
| 2021-12-08 | BCIP Life Sciences Associates, LP; BCLS II Investco, LP; BCLS II Investo (GP), LLC; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors II, LLC; Bain Capital Life Sciences Investors, LLC | Purchase (P) | Common Stock | 13,458 | USD 9.62 | USD 129,466 | SEC filing ↗ |
| 2021-10-26 | SV7 (IMF) GP LLP; SV7 Impact Medicine Fund LP | Purchase (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC filing ↗ |
| 2021-10-26 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt L.P.; Deerfield Mgmt V, L.P.; Flynn James E | Purchase (P) | Common Stock | 387,500 | USD 16.00 | USD 6,200,000 | SEC filing ↗ |
| 2021-10-26 | RiverVest Venture Fund IV, L.P. | Purchase (P) | Common Stock | 250,000 | USD 16.00 | USD 4,000,000 | SEC filing ↗ |
| 2021-10-26 | Four Pines Master Fund LP; Rock Springs Capital LLC; Rock Springs Capital Management LP; Rock Springs Capital Master Fund LP | Purchase (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC filing ↗ |
| 2021-10-26 | BAY CITY CAPITAL LLC | Purchase (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC filing ↗ |
| 2021-10-26 | Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund I, L.P. | Purchase (P) | Common Stock | 187,500 | USD 16.00 | USD 3,000,000 | SEC filing ↗ |
Form 4 evidence
7 transaction lines in the latest 365-day window; 58 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | Purchase (P) | Common Stock | 5,000 | USD 8.79 | USD 43,950 | SEC filing ↗ |
| 2026-01-02 | Frankenfield Christopher James | Sale (S) | Common Stock | 7,030 | USD 0.64 | USD 4,499 | SEC filing ↗ |
| 2026-01-02 | Brennan Kevin M. | Sale (S) | Common Stock | 1,826 | USD 0.64 | USD 1,169 | SEC filing ↗ |
Show recent Form 4 evidence (7 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | Purchase (P) | Common Stock | 5,000 | USD 8.79 | USD 43,950 | SEC filing ↗ |
| 2026-01-02 | Frankenfield Christopher James | Sale (S) | Common Stock | 7,030 | USD 0.64 | USD 4,499 | SEC filing ↗ |
| 2026-01-02 | Brennan Kevin M. | Sale (S) | Common Stock | 1,826 | USD 0.64 | USD 1,169 | SEC filing ↗ |
| 2026-01-01 | Russo Rene | Option exercise / conversion (M) | Common Stock | 44,250 | USD — | USD — | SEC filing ↗ |
| 2026-01-01 | Luptakova Katarina | Option exercise / conversion (M) | Common Stock | 16,625 | USD — | USD — | SEC filing ↗ |
| 2026-01-01 | Frankenfield Christopher James | Option exercise / conversion (M) | Common Stock | 19,375 | USD — | USD — | SEC filing ↗ |
| 2026-01-01 | Brennan Kevin M. | Option exercise / conversion (M) | Common Stock | 5,000 | USD — | USD — | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | XLO |
| CIK | 0001840233 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 58 transaction lines from 2021-10-26 to 2026-03-26 16 P purchase lines · 10 S sale lines · 32 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.